Kobe University group develops oral therapeutic vaccine candidate for treatment of chronic hepatitis C using transgenic probiotic Bifidobacteria

The group of Hiroshi HOTTA at Kobe University School of Medicine have engineered Bifidobacteria to express on their surface fusion protein CD8 epitopes and CD4 of NS3 protein necessary for inducing cellular immunity. If administered orally to the mice , cell-mediated immunity against HCV was induced

JST news release, March 20, 2014

Most popular posts: